Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 3,960 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total value of $468,111.60. Following the completion of the transaction, the chief executive officer now directly owns 189,762 shares of the company’s stock, valued at approximately $22,431,766.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Steven Leonard Chapman also recently made the following trade(s):
- On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84.
- On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20.
- On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52.
- On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53.
Natera Price Performance
Shares of NASDAQ NTRA traded up $1.99 during midday trading on Wednesday, reaching $126.73. 794,882 shares of the stock traded hands, compared to its average volume of 1,316,621. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock has a market capitalization of $15.67 billion, a PE ratio of -51.71 and a beta of 1.53. Natera, Inc. has a one year low of $37.67 and a one year high of $133.54. The company’s 50 day moving average is $123.31 and its 200 day moving average is $111.82.
Institutional Trading of Natera
Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Itau Unibanco Holding S.A. purchased a new stake in Natera during the 2nd quarter valued at $28,000. Quarry LP increased its stake in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC increased its stake in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the period. Tobam purchased a new stake in Natera in the second quarter worth $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Natera in the first quarter worth $83,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. BTIG Research upped their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Robert W. Baird increased their target price on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. TD Cowen increased their target price on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. UBS Group reduced their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $150.00 target price on shares of Natera in a report on Friday, September 13th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $125.69.
Get Our Latest Research Report on NTRA
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
- Five stocks we like better than Natera
- What is the FTSE 100 index?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- The Significance of Brokerage Rankings in Stock Selection
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Buy P&G Now, Before It Sets A New All-Time High
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.